ACCESS & RECORD / WHERE IT STANDS
Wolverine Legal Status, FDA 503A Category, and Compounding Access
The access ledger for BPC-157 TB-500, carved as it actually stands: a present-tense FDA Category 2 status, an active review on the calendar, and the lawful compounding pathway in general terms.
Where Wolverine legal status stands today
The Wolverine legal status question has a precise present-tense answer at the constituent level, because the blend itself has no regulatory identity. Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved therapeutic indication anywhere.
Both constituents currently sit in FDA 503A "Category 2" — bulk drug substances FDA has identified as those that may present significant safety risks. BPC-157 was placed in Category 2 effective with the FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization. "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" was placed in Category 2 in the same September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information. Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding, which means compounding pharmacy access is currently restricted for both constituents [14][15].
The status is under active review
The regulatory picture has clear forward momentum, and it is anchored on a scheduled fact rather than a prediction. Both constituents are under active FDA evaluation: "BPC-157 (free base)" and "BPC-157 acetate," along with "TB-500 (free base)" and "TB-500 acetate," appear on the published agenda of the Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as substances "being considered for inclusion on the 503A Bulks List" [16].
That is what is on the calendar, and that is all it is: a scheduled discussion of substances under evaluation. A PCAC meeting is advisory, and inclusion on a final 503A bulks list is decided by FDA rulemaking informed by that committee. Being discussed by PCAC is a step in evaluation, not a final listing decision [14]. Access for these peptides may expand in 2026 as that review proceeds — but no reclassification has occurred, no outcome is decided, and no date should be attached to any predicted result. The carved entry reads: under review, status unchanged.
How compounded access works, in general
Setting the two constituents aside, it helps to understand the lawful framework in general terms. Under the Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [14].
A legally compounded medication is prepared only after an individual patient is evaluated by a licensed prescriber — in person or through a compliant telehealth encounter — who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription. The preparation is then dispensed by a state-licensed 503A pharmacy or sourced from a 503B outsourcing facility [14]. Telehealth is one front-end channel to that prescriber evaluation; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription. Crucially, a compounder may use a bulk substance only if that ingredient is eligible under the 503A/503B rules — and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [14]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply anything.
Is the Wolverine Blend Legal?
The blend has no approved status anywhere, and neither constituent is an FDA-approved drug. Both BPC-157 and TB-500 currently sit in FDA 503A Category 2 — identified as potentially presenting significant safety risks — which places them outside FDA's enforcement-discretion policy for 503A compounding. Both are also prohibited in sport under the World Anti-Doping Agency's list [14][15].
BPC-157 and Compounding Pharmacy Access
BPC-157 is in FDA 503A Category 2 (effective with the September 29, 2023 update), so it is not within FDA's enforcement-discretion policy for 503A compounding, and routine compounding access is currently restricted while that status stands. BPC-157 is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for the 503A Bulks List — a scheduled evaluation, not a listing decision [14][16].
FDA 503A Status of the Blend
The blend has no 503A status of its own; status attaches to each constituent. Both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" are in 503A Category 2 effective with the FDA's September 29, 2023 update, citing immunogenicity and safety-information concerns. Both appear on the July 2026 PCAC agenda as candidates under evaluation for the 503A Bulks List [14][15][16].
FDA and WADA Status
Neither constituent is FDA-approved and the blend has no approved indication. FDA placed both BPC-157 and the TB-500 (LKKTETQ) fragment in 503A Category 2, outside the enforcement-discretion policy for compounding [14][15]. Both are WADA-prohibited: BPC-157 under the S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories [8].